By Helena Smolak
Novartis is scheduled to report results for the fourth quarter on Friday. Here is what you need to know.
CORE OPERATING PROFIT FORECAST: The Swiss pharmaceutical major is set to report $4.44 billion in core operating profit--one of its preferred metrics, which strips out exceptional items--for the quarter, according to a poll of 16 analysts by Visible Alpha. The company made $3.82 billion in the prior-year period.
SALES FORECAST: Novartis's sales are forecast at $12.78 billion, according to analysts' estimates compiled by Visible Alpha. This compares with $11.42 billion the year before.
Shares rose 5.1% over the last 12 months.
WHAT TO WATCH
--U.S. generics of aplastic anemia drug Promacta, leukemia treatment Tasigna and heart drug Entresto are expected from around mid-2025, but Novartis has guided for top and bottom-line growth in 2025, Jefferies analysts said. "Fears of no growth in 2025 from U.S. generic headwinds have largely been laid to rest," they said.
--Investors will focus on launch trends and management commentary around Kisqali following its recent approval in early breast cancer, according to UBS analysts. Industry watchers will also look out for an update on its cardiovascular drug candidate pelacarsen, its key late-stage trial this year, UBS said.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
January 29, 2025 10:19 ET (15:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。